05:05 PM EDT, 10/29/2024 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) late Tuesday reported Q3 non-GAAP net income of $0.91 per diluted share, up from $0.46 a year earlier.

Analysts polled by Capital IQ expected $0.79.

Revenue for the quarter ended Sept. 30 was $745.7 million, compared with $581.3 million a year earlier.

Analysts expected $703.3 million.

For 2024, the company is now projecting non-GAAP EPS of $3.25 to $3.35 on revenue of $2.79 billion to $2.83 billion. This is compared to $3.10 to $3.25 on revenue of $2.75 billion to $2.83 billion, previously.

Analysts are looking for $3.20 and $2.80 billion, respectively.

Price: 70.00, Change: +0.09, Percent Change: +0.13